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The ability of the leishmanial parasite UR6 to act as an immunoprophylactic and immunotherapeutic agent
against Leishmania donovani infection in BALB/c mice was investigated. Unlike the virulent L. donovani AG83
(MOHOM/IN/1983/AG83), UR6 given through intracardiac route failed to induce visceral infection, but when
it was injected subcutaneously, UR6 induced a short-lived and localized self-healing skin lesion. Priming of
peritoneal macrophages with UR6 in vitro induced superoxide (O2
2) generation, whereas similar experiments
with virulent AG83 inhibited O2
2 generation. It was observed that priming of mice with either live or sonicated
UR6 in the absence of any adjuvant provided strong protection against subsequent virulent challenge. Further,
UR6-primed infected mice not only displayed a strong antileishmanial delayed-type hypersensitivity (DTH)
response but also showed an elevated level of the serum antileishmanial immunoglobulin G2a (IgG2a) isotype,
whereas infected mice failed to mount any antileishmanial DTH response and showed an elevated level of IgG1.
This indicates that UR6 priming and subsequent L. donovani infection allowed the expansion of Th1 cells. Our
studies indicate that UR6 has potential to be used as an immunoprophylactic and immunotherapeutic agent
against experimental visceral leishmaniasis.
The protozoan parasite Leishmania causes at least three
major forms of human diseases, including cutaneous leishman-
iasis (CL), mucocutaneous leishmaniasis, and visceral leish-
maniasis (VL) (12). VL is the most severe systemic disease
among the three main categories of leishmaniasis (12). In
India, almost 44 million people in 28 districts of Bihar and 5.5
million people in 8 districts of West Bengal are at risk for VL
(47).
Chemotherapy of leishmaniasis has been restricted mainly to
the use of antimonials (5), despite cardiac and renal toxicity.
The emergence of drug resistance and nonavailability of pro-
phylactic agents are major obstacles to their control. However,
the development of protective immunity following spontane-
ous resolution of both CL (15) and VL (22) suggests that
perhaps the induction of protection by vaccination could be
feasible in the control of leishmaniasis.
Studies on mice and humans suggest that T-cell-mediated
immune responses play a central role in the outcome of leish-
maniasis (8). Preferential expansion of functionally distinct
CD41 T-cell subsets that are highly polarized to either the Th1
or Th2 pattern determines the outcome of the disease. Knowl-
edge about defense mechanisms in leishmaniasis can be ex-
pected to aid in establishing a strategy for developing such a
vaccine.
Development of a vaccine for CL has been the focus of much
attention. Certain subcellular fractions (or pure antigens) and
live, attenuated parasites have been implicated as potential
vaccine candidates (17). Early studies in animal models immu-
nized with killed parasites plus adjuvant have demonstrated
that reductions in the live parasite burden can also be achieved
in VL (17). Reports that many leishmanial antigens are cross-
reactive (27) motivated the use of a first-generation vaccine for
CL against VL (27, 28). The use of live Leishmania vaccine has
been abandoned because of problems associated with the vir-
ulence of available vaccine lines. These problems led to the
efforts to develop a safe, live Leishmania vaccine line by gene
replacement (45). Heterologous carriers like the Salmonella
system (23) that carried the gp63 gene of Leishmania major
and recombinant gp63 cloned in a plasmid have been used as
modern tools of genetic vaccination. But in all of these cases
adjuvant was required to achieve protection. In absence of
adjuvant, little protection was observed. In a recent report, it
has been shown that Leishmania donovani promastigotes en-
trapped in neutral liposomes conferred around 73% protection
in experimental VL (2).
Development of a safe and effective vaccine line is thus
besieged with problems. While peptide vaccines suffer from
poor immunogenicity and genetic restriction in the T-cell com-
partment, genetic vaccines are not likely to reach 100% pro-
tection because of their restrictiveness and lack of the full
repertoire of antigens involved in a protective immune re-
sponse (34, 46). For this reason there were various attempts at
vaccinations using attenuated or avirulent forms of Leishma-
nia. Gamma-irradiated Leishmania (38) or attenuated Leish-
mania derived from long-term culture in vitro (17) has been
shown to yield substantial protection in mice against subse-
quent challenge with L. major.
Recently we have reported that the leishmanial parasite
UR6 (MMOM/IN/1978/UR6) is highly effective as an immu-
noprophylactic and immunotherapeutic agent against L. dono-
vani infection in a hamster model (29). The leishmanial para-
site UR6 was found to stimulate superoxide generation in
hamster macrophages (Mfs), to display abundant message for
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KMP II, and to lack LPG (29). Interestingly, unlike the case for
other systems, UR6-mediated protection is observed in ab-
sence of any adjuvant. This observation prompted us to study
the efficacy of UR6 as an immunoprophylactic and immuno-
therapeutic agent against L. donovani infection in the murine
model.
MATERIALS AND METHODS
Animals, parasites, animal infection, and parasite burden. Four- to 6-week-
old BALB/c mice, reared in the Institute facility (originally brought from Jackson
Laboratory, Bar Harbor, Maine were used irrespective of sex. Leishmania strain
UR6 (MHOM/IN/1978/UR6) was originally isolated from the bone marrow
aspirate of a kala-azar patient and has been maintained in Ray’s modified
medium (37) for more than 20 years in our laboratory. L. donovani strain AG83
(MHOM/IN/1983/AG83) and L. major strain NIH Friedlin were maintained in
vitro in M-199 containing 10% fetal calf serum (FCS) as described before (29).
Amastigotes were prepared from the spleens of AG83-infected mice on a dis-
continuous Percoll gradient as described by Hart et al., (18). For infection, mice
were inoculated with 2 3 107 AG83 amastigotes or 2 3 107 promastigotes in 0.5
ml of saline through the tail vein (31).
Splenic and hepatic parasite burdens in mice were determined as described by
Stauber (43), and results were expressed as mean parasite number 6 standard
deviation (SD).
Transformation of amastigotes to promastigotes. Infected spleens were cul-
tured at 22°C for 5 to 7 days in Schneider’s Drosophila medium, supplemented
with 20% FCS for synchronized transformation of amastigotes to promastigotes.
Promastigotes were seen after 5 days, and thereafter the parasites were routinely
subcultured (40).
MAb and polyclonal antibodies. L. major-specific monoclonal antibodies
(MAb) 5E6-G11 and 2G11-H2 (isotype immunoglobulin G1 [IgG1]; ascities fluid
from mouse was the kind gift of E. Handman, The Walter and Eliza Hall
Institute of Medical Research, Melbourne, Australia). Mouse IgG1 and goat
anti-mouse IgG1 (heavy chain specific) were purchased from Sigma, St. Louis,
Mo.
Iodination of anti-mouse IgG1 and CS-RIA with promastigotes. Ten micro-
grams of goat anti-mouse IgG1 was iodinated by the chloramine-T method (14).
The specific activity of the 125I-labeled anti-IgG1 was 107,141 to 121,374 cpm/mg
of protein. The cell surface radioimmunoassay (CS-RIA) was carried out as
described elsewhere (16). The extent of binding of MAb 5E6-G11-H2 to leish-
manial parasites (promastigotes) was assessed by use of 125I-labeled anti-IgG1.
Nonspecific IgG1 was used as a control. Optimal dilution of MAb and secondary
Ab to perform CS-RIA was done as described elsewhere (29).
Preparation of heat-killed, sonicated, and formaldehyde-fixed UR6. Heat-
killed, formaldehyde-fixed, or sonicated forms of UR6 were prepared as de-
scribed previously (29).
Priming of mice with various forms of UR6. Mice were primed subcutaneously
(s.c.) as well as through the intravenous (i.v.) or intraperitoneal (i.p.) route either
with a graded number of live UR6 organisms or with its equivalent in the form
of heat-killed, sonicated, or formaldehyde-fixed parasites in 0.5 ml of saline.
Preparation of parasite antigen. Parasite antigen was prepared as described
elsewhere (29). Briefly, stationary-phase promastigotes were harvested, washed
three times in phosphate-buffered saline (PBS), and then resuspended in PBS at
a concentration of 5 3 108 promastigotes per ml. The material was frozen and
thawed five times in liquid nitrogen and then sonicated three times (for 30 s at
maximum output with a 1-min interval between each sonication) on a Labsonic-
2000 sonicator (Labonic L; B. Braun Melsungen AG, Melsungen, Germany).
The sonicated material was then centrifuged at 2,000 rpm for 10 min, and the
resulting supernatant was designated crude soluble antigen (CSA).
Assay of superoxide (O2
2) in Mfs. Superoxide (O22) generation in Mfs was
determined by nitroblue tetrazolium (NBT) reduction assay (30). Briefly, thio-
glycolate-induced peritoneal Mfs were adjusted to 4 3 106 per ml in RPMI 1640
medium (GIBCO) containing 10% FCS. One hundred microliters of sonicated
AG83 or UR6 (equivalent to 6 3 107 parasites/ml) was mixed with 200 ml of cell
suspension (equivalent to 8 3 106 Mfs) and allowed to adhere to 22-mm-
diameter glass coverslips. Mfs stimulated with lipopolysaccharide (LPS) (500
ng/ml; Sigma) were used as a positive control. After 3, 6, and 12 h of incubation
at 37°C in 5% CO2 in moist air, NBT (0.5 mg/ml) was added and the coverslips
were kept at 37°C for 1 h. The reaction was terminated with 200 ml of cold PBS,
and cells were fixed with ice-cold methanol and finally stained with 0.5% safra-
nin. Mfs showing blue color were scored, and results were expressed as percent
NBT-positive cells.
Assay of antileishmanial DTH response. The delayed-type hypersensitivity
(DTH) response in the infected and protected groups of BALB/c mice was
studied using CSA as an antigen as described elsewhere (9).
Infection of Mf culture. Splenic mononuclear cells isolated from BALB/c
mice (40) were suspended in RPMI 1640 medium supplemented with 10%
heat-inactivated FCS, 12 mM HEPES, and 50 U of gentamicin per ml (complete
medium) at a concentration of 106 cells/ml. The cells (4 ml) were allowed to
adhere to 60-mm-diameter petri dishes at 37°C in 5% CO2 in moist air. Three
hours after plating, the petri dishes were washed with warm RPMI 1640 medium
to remove nonadherent cells and were reincubated in complete medium. L.
donovani AG83 or UR6 promastigotes (5 3 107) were added to the culture at a
parasite/Mf ratio of 20:1. The petri dishes were kept at 37°C for 4 h to allow for
internalization of parasites and infected cultures were then thoroughly washed
with warm RPMI solution to remove free parasites and then incubated in com-
plete medium at 37°C for different time periods (12, 18, and 24 h). Culture
supernatant was collected and assayed for nitrite and tumor necrosis factor alpha
(TNF-a). Cultures without added parasites were run in parallel.
Measurement of nitrite production. Nitrite production in Mf culture super-
natant was assayed by the Griess reaction (13) using the nitric oxide assay kit of
Boehringer Mannheim. In brief, 80 ml of RPMI 1640 medium was incubated with
50 ml of 1% sulfanilide and 50 ml of 1% n-1-naphthylethylenediamine dihydro-
chloride in 2.5% H3PO4 in the presence of nitrate reductase (10 ml of a 1-U/ml
solution) at room temperature for 15 min. Nitrite was quantitated by measuring
the optical density at 550 nm against a standard solution of sodium nitrite. Nitrite
production in LPS-stimulated cultured Mfs was taken as the positive control.
Estimation of released TNF-a. TNF-a production in Mf culture supernatant
was measured with the Factor-Test-X mouse TNF-a enzyme-linked immunosor-
bent assay (ELISA) kit in a solid-phase ELISA using the multiple-antibody
sandwich principle (32). Released TNF-a was quantitated at 450 nm against a
murine TNF-a standard. TNF-a production in Staphylococcus aureus Cowan
1-stimulated cultured Mfs was taken as the positive control.
Collection of sera and assay for antileishmanial IgG1 and IgG2a. Sera were
prepared from the clotted blood of five or six mice for analysis by enzyme
immunoassay. The status of IgG1 and IgG2a in the sera of normal and infected
mice was studied by enzyme immunoassay as described previously (10). MAb
R616.7 and K123 were used as positive controls for mouse anti-IgG1 and anti-
IgG2a, respectively.
Statistical analysis. Results were expressed as means 6 SDs for individual sets
of experiments. In each experiment, about 5 to 10 animals were used in each
group. Each experiment was performed three to six times, and the representative
data from one set of these experiments are presented. The extent of variation
between experiments was within 10%. A one- or two-tailed Student t test for
analyzing significance was performed.
RESULTS
i.v. inoculation of UR6 and AG83 in BALB/c mice. BALB/c
mice (groups of six) were inoculated i.v. with 2 3 107 AG83
amastigotes or UR6 promastigotes, and at 5 months after in-
fection hepatic and splenic parasite burdens were determined.
It was observed that the parasite burden was very high in the
case of AG83-infected BALB/c mice, whereas UR6-infected
BALB/c mice failed to show any detectable parasites in the
spleen and liver (Fig. 1).
UR6-induced cutaneous lesions in BALB/c mice. Seven
BALB/c mice were inoculated with graded doses of UR6 (107,
108, and 109) s.c. It was observed that UR6 induced a very
short-lived, self-healing skin lesion (Fig. 2), and the size of the
lesion was directly proportional to the size of the UR6 inocu-
lum. On increasing the number of UR6 parasites inoculated,
the size of the lesion also increased. The lesion lasted for about
3 to 4 days and then tended to heal. No detectable parasites
could be observed in the visceral organs of these mice through-
out the period of investigation.
Ability of L. major-specific MAb (5E6-G11 and 2G11-H2) to
bind to leishmanial parasites. The ability of the L. major-
specific MAb 5E6-G11 and 2G11-H2 to bind to leishmanial
parasites was studied. It was observed that MAb 5E6-G11
showed maximum binding to L. major and minimum binding to
AG83, with an intermediate level of binding to UR6. On the
other hand, MAb 2G11-H2 showed maximum binding to L.
major and essentially comparable levels of binding to UR6 and
AG83 (Table 1).
Priming of mice with live UR6 s.c. before virulent challenge
and determination of splenic parasite burden. The ability of
UR6 to protect against virulent L. donovani (AG83) challenge
was studied. BALB/c mice were primed with graded doses of
UR6 as indicated in Table 2. The mice were divided into five
groups (A through E; eight mice in each group). In groups B
through E, each mouse was injected with UR6 twice at a
15-day interval, and 15 days after the second injection, animals
were infected with live AG83 amastigotes. At 83 days postin-
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fection, animals were sacrificed and the splenic parasite burden
was determined. Group A mice received saline instead of UR6,
whereas group E mice received only UR6. The mice receiving
107 (group B), 108 (group C), and 109 (group D) UR6 organ-
isms showed 36, 67.6, and 95.4% reductions in the splenic
parasite burden, respectively, compared to the infected con-
trols (group A). As expected, mice receiving only UR6 (group
E), failed to show any detectable parasites in the spleen.
The number of amastigotes in the spleen in relation to trans-
formed promastigotes recovered from the infected spleen
(groups A through E) cultured for 96 h in the medium was
calculated as described elsewhere (40). It was observed that the
percent reductions in the splenic parasite burdens for amasti-
gotes (as evident from the stamp smear) and promastigotes (as
evident from the cultured splenic sections) went essentially
hand in hand (Table 2).
Priming with live, sonicated, heat-killed, and formaldehyde-
fixed UR6 s.c. before virulent challenge. Ten mice in each
group were immunized s.c. with either 109 live UR6 organisms
(group B), 109 sonicated UR6 organisms (group C), 109 heat-
killed UR6 organisms (group D), or 109 formaldehyde-fixed
UR6 organisms (group E). The animals were primed three
times at 15-day intervals, and 30 days after the last priming,
animals were infected with virulent AG83 parasites. Mice
(groups A through E) were sacrificed on day 90 postinfection,
and the liver and splenic parasite burdens were determined
(Table 3). It was evident that although all three forms of UR6
tested provided essentially comparable levels of protection, the
sonicated UR6 was marginally more effective (the reductions
in the splenic and hepatic parasite burdens were 99.5 and
93.68%, respectively). For the rest of the experiments, 109
sonicated UR6 organisms were used.
Priming of mice with sonicated UR6 through intracardiac
i.v., i.p., and s.c. routes. Eight mice in each group were primed
through intracardiac i.v. (group B), i.p. (group C), and s.c.
(group D) routes, and the mice were infected with amastigotes
after the last injection and sacrificed 180 days after infection.
Injection of UR6 promastigotes s.c. induced 100% immunity,
in terms of both liver and splenic parasite burdens, against the
high-dose challenge with virulent AG83. Although this immu-
nity was not seen in the case of i.v. immunization with UR6
promastigotes, the i.p. route afforded an intermediate degree
of protection (62.69% for spleen and 95.50% for liver) (Ta-
ble 4).
Use of live or sonicated UR6 as an immunoprophylactic
agent. Thirty-day-infected mice were divided into three groups
(nine mice in each group). Group B mice were injected with
109 live UR6 organisms, group C mice were injected with 109
sonicated UR6 organisms, and group A infected mice received
only saline. All three groups were sacrificed on day 165 after
infection, and splenic and liver parasite burdens were deter-
mined. Mice receiving live UR6 (group B) showed reductions
in the splenic and liver parasite burdens to 97.46 and 82.7%,
respectively, with respect to saline-treated infected control
group (group A). Similar results were obtained for mice re-
ceiving sonicated UR6 (group C) (Table 5).
Superoxide generation in vitro in Mfs in response to
L. donovani UR6 or AG83 promastigotes. Peritoneal Mfs of
BALB/c mice were incubated for 3 h, 6 h, and 12 h with
sonicated UR6 or AG83 promastigotes, and the extent of su-
peroxide generation was assayed by NBT reduction assay. LPS
was used as a nonspecific stimulator of Mfs, and it was ob-
served that LPS stimulated the maximum level of O2
2 gener-
ation in Mfs as evident from the percentage of NBT-positive
FIG. 1. Parasite burdens in spleens and livers of BALB/c mice in a progres-
sive infection after inoculation with AG83 amastigotes and UR6 promastigotes
through the tail vein.
FIG. 2. Skin lesions in BALB/c mice in response to s.c. challenge with live
UR6. I, lesion at site of injection; II, healing response.
TABLE 1. Binding of L. major-specific MAb 5E6-G11 and
2G11-H2 to leishmanial parasites
Ab
Relative binding (mean cpm 6 SD) to:
L. major
Friedlin
Leishmania
strain UR6
L. donovani
AG83
5E6-G11 17,400 6 823.07 14,327 6 3,672 9,360 6 246.00
2G11-H2 20,286 6 5,532.40 14,441 6 2,442 14,232 6 420.00
Nonspecific IgG1 3,831 6 156.90 4,201 6 637.80 4,007 6 134.35
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cells. Incubation with sonicated UR6 promastigotes caused a
significantly higher number of NBT-positive cells than incu-
bation with AG83 promastigotes. When Mfs were incubat-
ed with medium alone, a basal level of NBT-positive cells was
observed (Fig. 3).
Antileishmanial DTH response and status of antileishma-
nial antibody in sera of infected and UR6-immunized BALB/c
mice. Normal BALB/c mice were divided into four groups
(groups I through IV; 7 mice in each group). Group III and IV
mice were injected thrice at 15-day intervals with 109 sonicated
UR6 organisms, while group I and II mice were injected thrice
at 15-day intervals with normal saline. Fifteen days after the
last injection, group II and IV mice were challenged with live
AG83 promastigotes, while group I and III mice received sa-
line. After 120 days of infection, using L. donovani CSA, DTH
was measured with a dial calliper. DTH was expressed as the
absolute footpad thickness increase, in 1022 mm (Fig. 4). In
each experiment, group I mice were immunized with the test
antigen. The increase in footpad thickness at 24 h in these mice
was taken as the background footpad swelling caused by the
eliciting antigen alone. All DTH data (specific DTH) are cor-
rected for the background reading. The DTH responses in
groups II, III, and IV were 0.21 6 0.06, 0, 0.02 6 0, and 0.95 6
0.22, respectively (Fig. 4).
The antileishmanial antibody isotype IgG2a and IgG1 status
in the sera of all of the above four groups was studied. It was
observed that antileishmanial IgG1 levels were comparable in
groups II, III, and IV (Fig. 5A). On the other hand, antileish-
manial IgG2a was found to be much elevated (Fig. 5B) in the
UR6-primed infected group (i.e., the protected group [group
IV]) compared to groups II and III.
Release of TNF-a. UR6 promastigotes were able to induce a
68-fold increase in TNF-a production in cultured Mfs. On the
other hand, AG83 induced only a 12.5-fold increase in TNF-a
formation. In the control experiments, S. aureus Cowan 1
caused a 92-fold increase in nitrite formation (Fig. 6A).
Nitrite production in cultured Mf supernatant. Incubation
of murine Mfs with UR6 promastigotes induced a 2.5-fold
increase in nitrite, compared to the 1.8-fold increase when
Mfs were challenged with AG83 promastigotes (Fig. 6B). LPS
caused a 3.2- to 3.8-fold increase in nitrite formation.
DISCUSSION
The present study was under taken to assess the protective
ability of the atypical leishmanial parasite UR6 against virulent
challenge with L. donovani AG83 in BALB/c mice. To date
prophylactic immunization against VL has required either the
use of an adjuvant (20) or the establishment of prior infection
with a low dose of the parasite (26). Without the use of adju-
vants like CFA, glucan, BCG, or liposomes, the efficacy was
found to be reduced quite dramatically. Although substantial
protective immunity could be induced by prophylactic immu-
nization with gamma-irradiated Leishmania tropica promastig-
otes (21), irradiated promastigotes are not suitable as the basis
of a vaccine. The importance of the present study is in estab-
lishing the fact that mice immunized with an atypical promas-
tigote (UR6) without adjuvant can acquire long-lasting resis-
TABLE 2. Comparison of promastigote recovery in in vitro culture and parasite burdens in spleens of mice after s.c. priming with
graded doses of live UR6 before infection with L. donovani AG83
Group
Priming with
live UR6
Infection with
AG83 on
day 0
Splenic parasite burden
(mean 6 SD)
% Reduction in splenic para-
site burden on day 83 with
respect to group A
No. of parasites trans-
formed in vitro cul-
ture (mean 6 SD)
% Reduction in trans-
formed promastigotes
with respect to group
A in in vitro cultureDay 30 Day 15
A 1 (1.5 6 0.2) 3 107 (4.8 6 0.12) 3 107
B 107 107 1 (9.6 6 0.21) 3 106 36.0a (3.1 6 0.1) 3 107 35.41c
C 108 108 1 (4.86 6 0.09) 3 106 67.6b (1.0 6 0.09) 3 107 79.16c
D 109 109 1 (6.8 6 0.08) 3 105 95.4c (3.5 6 0.04) 3 106 92.70c
E 109 109 2 NDd ND
a P , 0.01.
b P , 0.005.
c P , 0.0005.
d ND, parasite not detected.
TABLE 3. Parasite burdens in spleens and livers of BALB/c mice after priming with various forms of UR6 before
infection with L. donovani AG83a
Group
Priming with 109 UR6
organisms prior to infection
with AG83
Parasite count (mean 6 SD) in:
% Reduction in parasite
burden with respect
to group A in:
Spleen Liver Spleen Liver
A (2.70 6 0.966) 3 107 (5.13 6 0.66) 3 107
B Live UR6 (2.58 6 1.06) 3 105 (6.00 6 2.70) 3 106 99.04b 88.30e
C Heat-killed UR6 (4.80 6 2.30) 3 105 (1.33 6 0.834) 3 107 98.22b 74.03d
D Formaldehyde-fixed UR6 (2.28 6 0.98) 3 106 (3.20 6 1.14) 3 106 91.55c 93.76e
E Sonicated UR6 (1.35 6 0.35) 3 105 (1.35 6 0.77) 3 105 99.50b 93.68e
a All groups received AG83 on day 0, and splenic and liver parasite burdens were counted on day 90. Mice were primed with UR6 in days 60, 45, and 30 before
infection.
b P , 0.01.
c P , 0.025.
d P , 0.005.
e P , 0.0005.
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tance against relatively large infecting challenges that are
otherwise lethal due to systemic disease.
The leishmanial parasite UR6, unlike AG83, was unable to
visceralize (Fig. 1) but was able to induce a short-lived, self-
healing skin lesion in the BALB/c mice (Fig. 2) and showed
cross-reactivity with the L. major-specific MAb 5E6-G11 and
2G11-H2 (Table 1). Previously Sacks et al. (39) have shown
that L. tropica, a species historically associated with CL, caused
a mild VL. Earlier, we have demonstrated that UR6 priming in
hamsters offered protection against virulent L. donovani chal-
lenge (29). Hence, we became interested in studying the effi-
cacy of UR6 as an immunoprophylactic immunotherapeutic
agent in mice.
The UR6-mediated protection was found to be dependent
on the immunization regimen, i.e., (i) the size of the challenge,
(ii) the number of immunizations, and (iii) the form of the
parasite. It was observed that priming with increasing numbers
(107 to 109) of UR6 parasites resulted in a 36 to 95% reduction
in the splenic or liver parasite burden (Table 2). When BALB/c
mice were primed with different forms of UR6 (live, sonicated,
heat-killed, or formaldehyde-fixed UR6) before infection, the
reductions in splenic and liver parasitemias were in the range
of 91 to 99% and 88 to 93%, respectively. It was observed that
the priming with the sonicated form of UR6 resulted in the
maximum reduction in both splenic (99%) and hepatic (93%)
parasite burdens (Table 3). The best route of priming was seen
to be multiple s.c. immunization with equivalent to 109 UR6
organisms (Table 4). The most effective regimen was delin-
eated as multiple s.c. immunization with 109 UR6 organisms in
either the live or the sonicated form. This is in agreement with
the report that s.c. inoculation of L. major conferred a high
degree of protection in CBA mice (38), although Liew et al.
have reported opposite results (24). This discrepancy in the
results may be due to the difference in the mouse strains used
in the experiments. The percent reduction in the splenic par-
asite burden was further validated by comparison with the
recovered promastigotes from the in vitro culture of the
spleens from the same group of mice (Table 2). It was further
observed that UR6 priming was also effective in established
infection models (Table 5).
TABLE 4. Parasite burdens in spleens and livers of BALB/c mice
after priming through various routes before infection
with L. donovani AG83a
Group
Route
used for
priming
Parasite count
(mean 6 SD) in:
% Reduction in
parasite burden
with respect to
group A in:
Spleen Liver Spleen Liver
A (1.30 6 0.22) 3 108 (2.87 6 0.69) 3 108
B i.v. (1.44 6 0.95) 3 108 (6.27 6 3.25) 3 108 0b 0c
C i.p. (4.85 6 0.55) 3 107 (1.28 6 0.19) 3 107 62.69d 95.50d
D s.c. (2.53 6 0.98) 3 105 0 99.80d 100d
a All groups received AG83 on day 0, and splenic and liver parasite burdens
were counted on day 180. Mice were primed with UR6 on days 90, 60, and 30
before infection.
b P , 0.025.
c P , 0.05.
d P , 0.005.
TABLE 5. Parasite burdens in spleens and livers of BALB/c
mice given live or sonicated UR6 after infection
with L. donovani AG83a
Group
Priming of
infected mice
with 109 UR6
organisms
Parasite count
(mean 6 SD) in:
% Reduction
in parasite
burden with
respect to
group A in:
Spleen Liver Spleen Liver
A (1.50 6 0.10) 3 108 (3.70 6 0.26) 3 108
B Live UR6 (3.80 6 1.25) 3 106 (6.40 6 0.36) 3 107 97.46b 82.70b
C Sonicated UR6 (6.20 6 0.37) 3 106 (5.71 6 2.81) 3 107 95.66b 84.56b
a All groups received AG83 on day 0, and splenic and liver parasite burdens
were counted on day 165. Mice were primed with UR6 on days 30, 60, and 90
after infection.
b P , 0.005.
FIG. 3. Superoxide (O22) generation (in terms of NBT reduction) in peri-
toneal Mfs of BALB/c mice. Mfs were stimulated or not with LPS or incubated
in presence of UR6 or AG83. 1 ve, positive. Results are means and SDs.
FIG. 4. Antileishmanial DTH response in the BALB/c mice. I, normal mice;
II saline-treated infected mice; III, normal mice primed with 108 UR6 organisms;
IV, infected mice primed with 108 UR6 organisms. Sonicated UR6 was given to
the primed animals as described in the text. Animals were injected with UR6 on
days 0, 15, and 30, and 15 days after the last injection, animals were injected with
L. donovani amstigotes.
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Precisely how parasites are killed within activated Mfs is
presently unclear. Mf activation by lymphokines results in an
array of physiological and metabolic changes in the host cell,
some of which might theoretically contribute to the antileish-
manial effects (1). Evidence has been provided that the en-
hanced capacity of the activated Mfs to exert antileishmanial
effects is closely correlated with the ability of these cells to
secrete high levels of reactive oxygen intermediates (8). Since
UR6 induces O2
2 generation in Mfs, it is plausible that UR6
priming induced O2
2 generation and that this resulted in the
destruction of the intracellular parasites.
It has been shown that reactive nitrogen intermediates are
major effector molecules in the inhibition of intracellular pro-
liferation of L. major (8). The innate resistance of mice to
infection with L. major can be well correlated with the induc-
tion of Mf nitrate synthase for synthesis of nitric oxide (NO)
by gamma interferon and TNF-a (6). Studies on Mfs from
Lshr and Lshs congenic mice infected with L. donovani amas-
tigotes prior to priming and activation with recombinant
gamma interferon and LPS revealed a direct correlation be-
tween TNF-a release and nitrate production, indicating a def-
inite autocrine role for TNF-a in production of reactive nitro-
gen intermediates and leishmanicidal activity (6). We have
observed that nitrite and TNF-a production was higher in the
cultures of UR6-activated Mfs than in those activated by
AG83 promastigotes. Moreover, although only a basal level of
nitrite was produced on Mf activation by AG83 over a period
of time, nitrite production slowly increased with time in the
cultures of UR6-activated Mfs. There was a direct correlation
between TNF-a release and nitrite production by UR6-acti-
vated Mfs.
Patients with CL and VL recover after drug treatment and
gain resistance against reinfection as the antibody titer de-
creases and cell-mediated immunity is expressed, as assessed
by skin reactivity to parasite antigens (7, 35). The preferential
expansion of functionally distinct CD41 T-cell subsets that are
highly polarized to either the Th1 or Th2 pattern determines
the outcome of the disease. In order to assess the T-cell clones
implicated in UR6-mediated protection, we assayed for Th1
and Th2 cells indirectly in terms of the immunoglobulin isotype
compartment. Th1 and Th2 cells help B cells to produce IgG2a
and IgG1, respectively (33, 44). Susceptible mice infected with
L. major mount a Th2 response and produce IgG1 antibodies,
whereas the resistant mice suppress this activity and enhance
IgG2a responses (7). Some of our previous studies with L.
donovani indicated that both Th1 and Th2 cells coexist in the
spleens of infected BALB/c mice or the relatively susceptible
FIG. 5. Antileishmanial isotypes present in the sera of BALB/c mice.
FIG. 6. TNF-a (A) and nitric oxide (B) induction from BALB/c Mfs stim-
ulated with UR6 or AG83. Released TNF-a and nitric oxide were measured as
indicated in the text. (A) TNF-a released by BALB/c Mfs alone (I) or stimulated
with UR6 (III) or AG83 (IV) was compared to that released by Mfs stimulated
with S. aureus Cowan 1 (1,850 pg/ml) (II) (B) Nitric oxide released by BALB/c
Mfs stimulated with AG83 or UR6 was corrected for the background stimula-
tion with Mfs alone. For comparison, the nitric oxide released by LPS-stimu-
lated Mfs was 23.8, 22.0, and 23.7 mM at 12, 18, and 24 h, of incubation,
respectively. The data shown represent one experiment of five.
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C57BL/6 mice, whereas the antileishmanial T-cell response
was biased towards a Th1 response in the resistant B6C-H-
2Bm12 strain (4, 42). IgG1 titers increased in uncontrolled
infections and remained lower in association with regression
(Fig. 5). On the other hand, IgG2a titers were higher in the
case of UR6-protected animals. The effective stimulation of
the IgG2a isotype has thus been associated with the presence
of antileishmanial Th1 cells in the repertoire. Here, UR6 prim-
ing in infected mice allowed the preferential expansion of Th1
cells.
A positive DTH response towards leishmanial antigens is an
indication of cell-mediated immunity, and there are reports of
an association between the DTH response and protection in
the L. major system (11, 19, 41). Development of DTH in
UR6-immunized infected mice, in contrast with its suppression
in nonimmunized controls, coincided with control or progres-
sion of disease in the respective groups. Thus, generation of
suppression of DTH in response to L. donovani infection in
BALB/c mice is abrogated by effective prophylactic immuni-
zation.
Our method of priming was quite distinct and novel because
it did not require any adjuvant, unlike the case for other sys-
tems. In other systems, Corynebacterium parvum (17) or glucan
(20) was used as an adjuvant with leishmanial parasites. Ali
and Afrin have even demonstrated the use of neutral (3) and
positively charged (2) liposomes as adjuvants in experimental
visceral leishmaniasis in both hamster and mouse models. Re-
cently, Rivier et al. (38) obtained 39 to 53% protection con-
ferred by gp63 in the absence of adjuvant, which again in-
creased (64 to 68%) in the presence of an adjuvant like C.
parvum or BCG37. In experimental L. donovani infection the
extent of protection of reported by others (2, 3, 20, 25, 36) was
up to 60 to 80%, and in our case the maximum reduction in
parasite burden that could be achieved in the murine model
was 95 to 99% in the spleen and 80 to 90% in the liver.
Previously we have shown that priming of hamsters with either
live or sonicated UR6 in the absence of any adjuvant provided
strong protection against virulent challenge. UR6-mediated
protection was also observed in hamsters with established in-
fection. Further, UR6-primed infected hamsters displayed a
greatly extended life span compared to infected hamsters (29).
To our knowledge, this is the first report showing that an
attenuated parasite can be used for immunotherapy in the
murine model, in the absence of an adjuvant, against experi-
mental VL. Studies are under way to prime mice in combina-
tion with immunostimulatory agents such as BCG together
with UR6 to eliminate the residual parasites.
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